Currently, CDK1 inhibitors, such as Rigosertib and Zotiraciclib, are in Phase III clinical trials and have shown potential in treating PDAC and gliomas (O'Neil et al., 2015; Le Rhun et al., 2024). Here, CDK1 is linked to glioma.